Oppenheimer reiterated coverage on Aptose Biosciences with a new price target

3/24/21 6:57:14 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Oppenheimer reiterated coverage of Aptose Biosciences with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APTO

Date	Price Target	Rating	Analyst
12/21/2021	$14.00 → $12.00	Buy	HC Wainwright & Co.
11/12/2021	$9.00 → $14.00	Buy	HC Wainwright & Co.